Cubist Systematic Strategies’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

Cubist Systematic Strategies’s Portfolio LUMO Stock Details LUMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-1,490	Closed	-$64K	–	2128
2018 Q2	$64K	Buy	1,490 +54	+4%	+$2.47K	﹤0.01%	1615
2018 Q1	$94K	Sell	1,436 -913	-39%	-$64.7K	0.01%	1603
2017 Q4	$171K	Buy	+2,349	New	+$194K	0.01%	1579
2015 Q4	–	Sell	-1,782	Closed	-$575K	–	1979
2015 Q3	$575K	Buy	1,782 +969	+119%	+$426K	0.03%	880
2015 Q2	$324K	Buy	+813	New	+$345K	0.02%	1193

Other funds holding LUMO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cubist Systematic Strategies's LUMO Position: Q3 2018 in Review

Cubist Systematic Strategies sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q3 2018, closing a stake of 1,490 shares — an estimated $64K sold.

Cubist Systematic Strategies first reported a position in LUMO in Q2 2015 and held it in 5 quarters. The position peaked at $575K in Q3 2015. 92 funds tracked by Wall St. Rank hold LUMO as of Q3 2018.

Cubist Systematic Strategies reported no remaining Lumos Pharma, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
Cubist Systematic Strategies sold 1,490 Lumos Pharma, Inc. Common Stock shares in Q3 2018, an estimated $64K.
Cubist Systematic Strategies first reported a position in Lumos Pharma, Inc. Common Stock in Q2 2015 and held it in 5 quarters.
Cubist Systematic Strategies's Lumos Pharma, Inc. Common Stock position peaked at $575K in Q3 2015.
92 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q3 2018.

Based on Cubist Systematic Strategies's 13F filing for Q3 2018, filed 14 Nov 2018.